Rani Therapeutics Holdings Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Rani Therapeutics Holdings şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-13.9%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-13.9%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Does Rani Therapeutics Holdings (NASDAQ:RANI) Have A Healthy Balance Sheet?

Jul 16

Is Rani Therapeutics Holdings (NASDAQ:RANI) Weighed On By Its Debt Load?

Mar 20

Rani Therapeutics enters $45M loan agreement to support advancement and pipeline development

Aug 08

We're Not Very Worried About Rani Therapeutics Holdings' (NASDAQ:RANI) Cash Burn Rate

Feb 13

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: RANI şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: RANI şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Rani Therapeutics Holdings Piyasaya Karşı Temettü Getirisi

RANI temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (RANI)	n/a
Pazarın Alt %25'i (US)	1.3%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Pharmaceuticals)	2.4%
Analist tahmini (RANI) (3 yıla kadar)	0%

Önemli Temettü: RANI şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, RANI şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: RANI şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: RANI herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Rani Therapeutics Holdings Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist

Rani Therapeutics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $9.999955 million.

Does Rani Therapeutics Holdings (NASDAQ:RANI) Have A Healthy Balance Sheet?

Rani Therapeutics Holdings, Inc., Annual General Meeting, May 29, 2024

New minor risk - Share price stability

Is Rani Therapeutics Holdings (NASDAQ:RANI) Weighed On By Its Debt Load?

Rani Therapeutics Holdings, Inc. to Report Q4, 2023 Results on Mar 20, 2024

Rani Therapeutics Holdings, Inc. to Report Q4, 2023 Results on Mar 20, 2024

New minor risk - Market cap size

Rani Therapeutics Holdings, Inc. Announces Positive Topline Results from Phase 1 Study of Oral Anti-Interleukin 12/23 Antibody (RT-111)

New minor risk - Market cap size

Rani Therapeutics Holdings, Inc. Announces Preclinical Data Regarding A Imimolecular Triagonist Molecule Delivered Via Endoscope

Independent Director recently bought US$102k worth of stock

New major risk - Financial position

Rani Therapeutics Holdings, Inc. Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill Technology Platform

Price target decreased by 9.9% to US$20.50

Rani Therapeutics Holdings, Inc. Announces Preclinical Data Supporting the Safety and Tolerability of the RaniPill® Drug Delivery Platform Following 60-Day Repeat Administration

Rani Therapeutics Holdings, Inc. Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

Rani Therapeutics Holdings, Inc. Initiates Phase 1 Study of Rt-111 (Ranipill® Containing Ustekinumab Biosimilar, Ct-P43)

Rani Therapeutics Holdings, Inc. Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

New major risk - Financial position

Rani Therapeutics Holdings, Inc. Appoints Kate Mckinley as Chief Business Officer

Rani Therapeutics Holdings, Inc. Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study

High number of new directors

Rani Therapeutics Holdings, Inc. Announces New RT-111 Development Program and Provides Corporate Update

Executive Chairman recently sold US$854k worth of stock

Price target decreased to US$24.67

Rani Therapeutics Holdings, Inc. Announces Positive Topline Results from Phase 1 Study of RT-102 in Osteoporosis

Rani Therapeutics Holdings, Inc. announced that it expects to receive $45 million in funding from Avenue Capital Group

Rani Therapeutics enters $45M loan agreement to support advancement and pipeline development

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new directors

Rani Therapeutics Holdings, Inc., Annual General Meeting, May 25, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Rani Therapeutics Holdings, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2021

We're Not Very Worried About Rani Therapeutics Holdings' (NASDAQ:RANI) Cash Burn Rate

Less than half of directors are independent

Third quarter 2021 earnings released: US$0.16 loss per share

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin